AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27724978 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Triage Algorithm (CTA)
Number of subjects: 50000
Study 27724978 — intervention group
Group type: COMPARATOR
Intervention: Danish Emergency Process Triage (DEPT)
Number of subjects: 50000
Study 24704626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) therapy alone
Number of subjects: 2385
Study 24704626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) and statin therapy
Number of subjects: 2385
Study 24704626 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy alone
Number of subjects: 2385
Study 22520120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavin-M1 (10(6.3)FFU/dose) - 2 doses, 2 months apart (Group 2H)
Number of subjects: 160
Study 22520120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavin-M1 (10(6.0)FFU/dose) - 2 doses, 2 months apart (Group 2L)
Number of subjects: 160
Study 22520120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavin-M1 (10(6.3)FFU/dose) - 3 doses, 1 month apart (Group 3H)
Number of subjects: 160
Study 22520120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavin-M1 (10(6.0)FFU/dose) - 3 doses, 1 month apart (Group 3L)
Number of subjects: 160
Study 22520120 — intervention group
Group type: COMPARATOR
Intervention: Rotarix™ (10(6.5)CCID(50)/dose) - 2 doses, 1 month apart
Number of subjects: 160
Study 22520120 — intervention group
Group type: COMPARATOR
Intervention: Rotarix™
Number of subjects: 160
Study 22520120 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavin-M1
Number of subjects: 160
Study 20329567 — intervention group
Group type: EXPERIMENTAL
Intervention: human derived FSH
Number of subjects: 115
Study 20329567 — intervention group
Group type: COMPARATOR
Intervention: recombinant FSH
Number of subjects: 115
Study 18418975 — intervention group
Group type: EXPERIMENTAL
Intervention: Egb761 (Ginkgo biloba extract) with chemotherapy (4 cycles of PA protocol)
Number of subjects: 60
Study 16192262 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched with probiotics (6 x 10^9 CFU of Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus) and 10 mg of zinc/day
Number of subjects: 65
Study 16192262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 65
Study 16192262 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched with probiotics and zinc
Number of subjects: 65
Study 12814810 — intervention group
Group type: EXPERIMENTAL
Intervention: Yasmin (30 microg ethinylestradiol and 3 mg drospirenone)
Number of subjects: 0
Study 12814810 — intervention group
Group type: COMPARATOR
Intervention: Marvelon (30 microg ethinylestradiol and 150 microg desogestrel)
Number of subjects: 0
Study 12814810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Yasmin and Marvelon
Number of subjects: 0
Study 11103175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram kg‐1
Number of subjects: 180
Study 11103175 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg kg‐1
Number of subjects: 180
Study 11103175 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (Control)
Number of subjects: 180
Study 8973752 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neuropeptide Y (NPY) levels
Number of subjects: 220
Study 8973752 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 220
Study 8973752 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 220
Study 8973752 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-cholesterol
Number of subjects: 220
Study 1731027 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with bacteriologic efficacy of 100%
Number of subjects: 293
Study 1731027 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with bacteriologic efficacy of 27% (consistent with no antibacterial therapy)
Number of subjects: 293
Study 1731027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanocentesis and culture before and during therapy
Number of subjects: 293
Study 1731027 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanocentesis before therapy and assessment of clinical efficacy
Number of subjects: 293
Study 1731027 — intervention group
Group type: EXPERIMENTAL
Intervention: No tympanocentesis and assessment of clinical efficacy
Number of subjects: 293
Study 6690196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin 100 ng h‐1 kg‐1
Number of subjects: 9
Study 6690196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin 500 ng h‐1 kg‐1
Number of subjects: 9
Study 30741864 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction equation 1 using height and body mass as covariates
Number of subjects: 66
Study 30741864 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction equation 2 using body composition parameters
Number of subjects: 66
Study 30741864 — intervention group
Group type: EXPERIMENTAL
Intervention: Average resting metabolic rate (RMR) assessment
Number of subjects: 66
Study 30741864 — intervention group
Group type: COMPARATOR
Intervention: Comparison of body composition across sports
Number of subjects: 66
Study 30741864 — intervention group
Group type: COMPARATOR
Intervention: Correlation of RMR with physical parameters
Number of subjects: 66
Study 30229683 — intervention group
Group type: EXPERIMENTAL
Intervention: Banxia Xiexin decoction
Number of subjects: 27
Study 30229683 — intervention group
Group type: COMPARATOR
Intervention: CPT‐11
Number of subjects: 27
Study 26224242 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance learning (n=53)
Number of subjects: 97
Study 26224242 — intervention group
Group type: COMPARATOR
Intervention: Face to face training (Control group, n=44)
Number of subjects: 97
Study 24809787 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 60
Study 24809787 — intervention group
Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 60
Study 24809787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 60
Study 22994106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mexidol (300 mg daily for 2 weeks)
Number of subjects: 0
Study 22994106 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of primary open-angle glaucoma
Number of subjects: 0
Study 20038730 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy for three cycles followed by gefitinib 250 mg orally once daily, until disease progression (arm B)
Number of subjects: 604
Study 20038730 — intervention group
Group type: COMPARATOR
Intervention: Platinum-doublet chemotherapy up to six cycles (arm A)
Number of subjects: 604
Study 20038730 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-doublet chemotherapy for three cycles followed by gefitinib 250 mg orally once daily (arm B)
Number of subjects: 604
Study 17572319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (500 mg in 48 hours via elastomeric pump)
Number of subjects: 96
Study 17572319 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (250 mL as placebo)
Number of subjects: 96
Study 16175565 — intervention group
Group type: COMPARATOR
Intervention: Treatment for SAD (exact intervention details not specified)
Number of subjects: 0
Study 16175565 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders to treatment
Number of subjects: 0
Study 16175565 — intervention group
Group type: COMPARATOR
Intervention: Patients who dropped out of the study
Number of subjects: 0
Study 11804991 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg)
Number of subjects: 18
Study 11804991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10825863 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste
Number of subjects: 19
Study 10825863 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 19
Study 8566936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 12
Study 8566936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2884856 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 12 mg (range 1 to 16)
Number of subjects: 126
Study 2884856 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 91.8 mg (range 50 to 100)
Number of subjects: 126
Study 29579254 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendril plot visualization of adverse events
Number of subjects: 0
Study 29579254 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27208464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 60
Study 27208464 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 60
Study 26654215 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Patient Interaction (NPI) - 1-hour small-group session with a patient discussing options counseling and decision to terminate pregnancy.
Number of subjects: 135
Study 26654215 — intervention group
Group type: COMPARATOR
Intervention: Control - Standard curriculum only.
Number of subjects: 135
Study 26654215 — intervention group
Group type: EXPERIMENTAL
Intervention: NPI
Number of subjects: 135
Study 26654215 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study 23981369 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (2 sessions/week for 4 weeks)
Number of subjects: 127
Study 23981369 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control group)
Number of subjects: 127
Study 20962916 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and epigallocatechin-3-gallate (EGCG) with exercise (EX-Act)
Number of subjects: 27
Study 20962916 — intervention group
Group type: COMPARATOR
Intervention: Placebo with exercise (EX-PL)
Number of subjects: 27
Study 20962916 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and epigallocatechin-3-gallate (EGCG) without exercise (NEX-Act)
Number of subjects: 27
Study 20962916 — intervention group
Group type: COMPARATOR
Intervention: Placebo without exercise (NEX-PL)
Number of subjects: 27
Study 18156639 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol for replacement therapy
Number of subjects: 19
Study 18156639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20004545 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aids (DAs) with additional information about competing health risks
Number of subjects: 663
Study 20004545 — intervention group
Group type: COMPARATOR
Intervention: Decision aids (DAs) without additional information about competing health risks
Number of subjects: 663
Study 15695960 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 18
Study 15695960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12218723 — intervention group
Group type: EXPERIMENTAL
Intervention: EMTDS 0.025 mg/day
Number of subjects: 355
Study 12218723 — intervention group
Group type: EXPERIMENTAL
Intervention: EMTDS 0.05 mg/day
Number of subjects: 355
Study 12218723 — intervention group
Group type: EXPERIMENTAL
Intervention: EMTDS 0.075 mg/day
Number of subjects: 355
Study 12218723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 9468457 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (2 ng Ang II/kg per min)
Number of subjects: 15
Study 9468457 — intervention group
Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 15
Study 8194508 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg elemental zinc (as zinc sulphate) for 7 days
Number of subjects: 24
Study 8194508 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg elemental zinc (as zinc sulphate) for 7 days
Number of subjects: 24
Study 3285809 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 105
Study 3285809 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin-clindamycin
Number of subjects: 105
Study 11171824 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal lipid infusion (L-2)
Number of subjects: 24
Study 11171824 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-A antagonist dexloxiglumide (5 mg/kg/h)
Number of subjects: 24
Study 11171824 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 24
Study 11171824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30222021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral bitewing radiographs (BTW)
Number of subjects: 241
Study 30222021 — intervention group
Group type: COMPARATOR
Intervention: Periapical radiographs (PA)
Number of subjects: 241
Study 30249507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (260 mg for patients weighing 35-55 kg, 390 mg for patients weighing >55 kg and ≤85 kg, and 520 mg for patients weighing >85 kg) followed by subcutaneous injections of 90 mg every 8 weeks.
Number of subjects: 102
Study 30249507 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenous infusion at week 0 followed by subcutaneous injections every 8 weeks.
Number of subjects: 102
Study 30249507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 102
Study 30249507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 27305046 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clinical stability
Number of subjects: 580
Study 25407020 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day opioid substitution treatment (methadone)
Number of subjects: 20
Study 25407020 — intervention group
Group type: COMPARATOR
Intervention: Baseline questionnaires at recruitment
Number of subjects: 20
Study 25407020 — intervention group
Group type: COMPARATOR
Intervention: Regular health evaluation paired with low-barrier access to treatment
Number of subjects: 20
Study 25407020 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 month follow-up
Number of subjects: 20
Study 22308967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-leadership training
Number of subjects: 0
Study 22308967 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19858703 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoBarrier Gastrointestinal Liner
Number of subjects: 41
Study 19858703 — intervention group
Group type: COMPARATOR
Intervention: Diet control group
Number of subjects: 41
Study 18035193 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg PO QD for 24 months
Number of subjects: 171
Study 18035193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 16303729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with benazepril 5 mg and losartan 25 mg
Number of subjects: 24
Study 16303729 — intervention group
Group type: COMPARATOR
Intervention: Benazepril alone (higher dose)
Number of subjects: 24
Study 16303729 — intervention group
Group type: COMPARATOR
Intervention: Losartan alone (higher dose)
Number of subjects: 24
Study 16303729 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 24
Study 12145222 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat diet (M) with 9% energy as C18:1cis (oleic acid)
Number of subjects: 25
Study 12145222 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat diet (S) with 9% energy as palmitic acid
Number of subjects: 25
Study 12145222 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acid diet (T) with 9% energy as C18:1trans
Number of subjects: 25
Study 9527194 — intervention group
Group type: EXPERIMENTAL
Intervention: DIP + APR
Number of subjects: 115
Study 9527194 — intervention group
Group type: COMPARATOR
Intervention: DIP
Number of subjects: 115
Study 7629898 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral buffered deferoxamine solution (5 mg/kg elemental iron)
Number of subjects: 7
Study 7629898 — intervention group
Group type: COMPARATOR
Intervention: Control phase (5 mg/kg elemental iron alone)
Number of subjects: 7
Study 2624725 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 29
Study 2624725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 779516 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltose treatment (drinks sweetened with maltose 2 hours before operation)
Number of subjects: 50
Study 779516 — intervention group
Group type: COMPARATOR
Intervention: Starved group (control)
Number of subjects: 50
Study 31641203 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT + RT
Number of subjects: 22
Study 31641203 — intervention group
Group type: COMPARATOR
Intervention: TRT
Number of subjects: 22
Study 30879908 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming system group
Number of subjects: 96
Study 30879908 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed intravenous fluid group
Number of subjects: 96
Study 30879908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 28399624 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 18
Study 28399624 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study 25925033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (3mg/kg infused over 1h)
Number of subjects: 45
Study 25925033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23021990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued condition (after performing repeated sit‐to‐stand movement)
Number of subjects: 30
Study 23021990 — intervention group
Group type: COMPARATOR
Intervention: Rested condition
Number of subjects: 30
Study 21756299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral based group intervention for children with CI (called 'Op Koers')
Number of subjects: 0
Study 21756299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral based group intervention for children with CI combined with a parent program
Number of subjects: 0
Study 21756299 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 19629674 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 44
Study 19629674 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (leuprolide acetate 0.15 mg)
Number of subjects: 44
Study 16984503 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalazine 1.2 g/day
Number of subjects: 38
Study 16984503 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalazine 2.4 g/day
Number of subjects: 38
Study 16984503 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalazine 4.8 g/day
Number of subjects: 38
Study 12532113 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (omega-3 fatty acids)
Number of subjects: 616
Study 11271083 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (5‐7.5 cmH2O)
Number of subjects: 9
Study 11271083 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPAP)
Number of subjects: 9
Study 10160021 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2069772 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mEq KCl/day
Number of subjects: 0
Study 6827873 — intervention group
Group type: EXPERIMENTAL
Intervention: Category rating scale with evenly distributed values across the response scale
Number of subjects: 0
Study 6827873 — intervention group
Group type: EXPERIMENTAL
Intervention: Category rating scale with items from the top of the scale
Number of subjects: 0
Study 6827873 — intervention group
Group type: EXPERIMENTAL
Intervention: Category rating scale with items with low values
Number of subjects: 0
Study 6827873 — intervention group
Group type: EXPERIMENTAL
Intervention: Category rating scale with items with low and high values (but not middle range)
Number of subjects: 0
Study 6827873 — intervention group
Group type: EXPERIMENTAL
Intervention: Category rating scale with items with medium values
Number of subjects: 0
Study 6827873 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli that are not health case descriptions with poorly defined response continuum
Number of subjects: 0
Study 31470599 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of non-animal chondroitin sulfate daily for 12 weeks
Number of subjects: 60
Study 29327032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton pad filtration
Number of subjects: 63
Study 29327032 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation
Number of subjects: 63
Study 29327032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedimentation
Number of subjects: 63
Study 26699729 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 72
Study 26699729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25022777 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 50
Study 25022777 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 50
Study 22171907 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Education Programme for Parkinson's disease (PEPP)
Number of subjects: 64
Study 22171907 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of PD patients
Number of subjects: 64
Study 20921313 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir with antacid
Number of subjects: 12
Study 20921313 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir alone
Number of subjects: 12
Study 17931943 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal Tulsa retreatment system
Number of subjects: 45
Study 17931943 — intervention group
Group type: COMPARATOR
Intervention: Hedström files with chloroform
Number of subjects: 45
Study 17931943 — intervention group
Group type: COMPARATOR
Intervention: K-flex files
Number of subjects: 45
Study 16361918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 to 5 units of PRBCs
Number of subjects: 102
Study 16361918 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 to 10 units of PRBCs
Number of subjects: 102
Study 16361918 — intervention group
Group type: EXPERIMENTAL
Intervention: greater than 10 units of PRBCs
Number of subjects: 102
Study 16361918 — intervention group
Group type: EXPERIMENTAL
Intervention: More units of PRBCs during the first 24 hours
Number of subjects: 102
Study 11975149 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use learning of transformations
Number of subjects: 0